Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States
DOI: https://doi.org/10.2147/dddt.s461771
IF: 4.3188
2024-06-15
Drug Design Development and Therapy
Abstract:Wanjun Bai, 1 Xue Sun, 1 Bo Qiu, 1 Caihui Guo, 1 Haojing Song, 1 Yiting Hu, 1 Xueyuan Zhang, 2 Peihua Yin, 3 Xiaoru Wang, 3 Zhanjun Dong 1 1 Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, Hebei, People's Republic of China; 2 Center for Clinical Pharmacology, Shanghai Innovstone Therapeutics Limited, Shanghai, People's Republic of China; 3 Center for Clinical Pharmacology, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, People's Republic of China Correspondence: Zhanjun Dong, Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, No. 348 Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province, 050051, People's Republic of China, Tel +86 311 85988604, Email Objective: This study compared the pharmacokinetics, safety and bioequivalence (BE) of generic and original apremilast tablets in healthy Chinese subjects under fasting and postprandial conditions, providing sufficient evidence for abbreviated new drug application. Methods: A randomized, open-label, two-formulation, single-dose, two-period crossover pharmacokinetic study was performed. Thirty-two eligible healthy Chinese subjects were enrolled in fasting and postprandial studies, respectively. In each trial, subjects received a single 30-mg dose of the test or reference apremilast tablet, followed by a 7-day washout interval between periods. Serial blood samples were obtained for up to 48 h post-intake in each period, and the plasma concentrations of apremilast were determined by a validated method. The primary pharmacokinetic (PK) parameters, including the maximum plasma concentration (C max ), the areas under the plasma concentration–time curve (AUC 0-t , AUC 0-∞ ), were calculated using the non-compartmental method. The geometric mean ratios of the two formulations and the corresponding 90% confidence intervals (CIs) were acquired for bioequivalence analysis. The safety of both formulations was also evaluated. Results: Under fasting and postprandial states, the PK parameters of the test drug were similar to those of the reference drug. The 90% CIs of the geometric mean ratios of the test to reference formulations were 94.09– 103.44% for C max , 94.05– 103.51% for AUC 0-t , and 94.56– 103.86% for AUC 0-∞ under fasting conditions, and 99.18– 112.48% for C max , 98.79– 106.02% for AUC 0-t , and 98.95– 105.89% for AUC 0-∞ under postprandial conditions, all of which were within the bioequivalence range of 80.00– 125.00%. Both formulations were well tolerated, and no serious adverse events occurred during the study. Conclusion: The trial confirmed that the PK parameters of the generic and original apremilast tablets were bioequivalent in healthy Chinese subjects under fasting and postprandial states, which met the predetermined regulatory standards. Both formulations were safe and well tolerated. Clinical Trial Registration: chinaDrugtrials.org.cn, identifier CTR20191056 (July 30, 2019); chictr.org.cn, identifier ChiCTR2300076806 (October 19, 2023). Keywords: apremilast, psoriasis, pharmacokinetics, bioequivalence, safety Psoriasis is a chronic immune-mediated skin disease that affects more than 125 million people worldwide. 1,2 There are a variety of phenotypes of psoriasis, but the plaque or psoriasis vulgaris is the most frequent and most easily recognized. 3 It is characterized by well demarcated, salmon-pink plaques covered in silvery scales in white skin and of grey plaques in black skin. 3 Symptoms include itching, burning and soreness. Psoriasis can manifest at any age, and in men and women, it occurs equally. It can present earlier in women, with a bimodal onset at the age of 16–22 years and 55–60 years. 3,4 Patients with psoriasis experience substantial comorbidities, including psoriatic arthritis, cardiometabolic diseases, psychiatric disorders, and negative effects on quality of life. 1 The pathogenesis of psoriasis is associated with an increased release of pro-inflammatory cytokines from immune-related cells and chronic activation of the innate and adaptive immune systems. 2,3 Therefore, systemic treatments with non-biological and biological agents that target both immune systems and skin are the most appropriate therapies for psoriasis. Non-biological agents such as methotrexate, acitretin, cyclosporine, and fumaric acid ester derivatives are conventionally prescribed in case of moderate or severe psoriasis. 2,5,6 However, no -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal